News

13 Jan 2017

CEO Dr David Bunton: Finalist - Annual Life Science Award 2017

ReproCELL Europe Ltd's CEO, Dr David Bunton, is one of the finalists nominated for the Life Science Business Leadership Award, part of Scotland's Annual Life Science Awards and Dinner, 2017.
Read More >>

22 Nov 2016

Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products

ReproCELL announces an entrustment contract with Healios K.K. (headquarters: Minato Ward, Tokyo; president and CEO: Tadanao Kagimoto; hereafter, Healios) for sample testing support of human clinical trials conducted by Healios, as well as the formation of said contract on the same day.
Read More >>

16 Nov 2016

Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development

Today, ReproCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. (headquarters: Naka-ku, Yokohama; CEO: Kazuyoshi Miyajima; henceforth, FANCL) for the development of a 3D model system derived from human iPS cells.
Read More >>

14 Nov 2016

Joint enterprise - Development of Drug Discovery Applications Using Neurons Derived from iPS Cells

Joint Enterprise of Keio University and Juntendo University - Notice regarding inclusion in Relevant Leading Businesses to Receive Assistance in the Special District of Yokohama City for the project of Development of Drug Discovery Applications Using Neurons Derived from iPS Cells
Read More >>

1 2 3 4 >>

CEO Dr David Bunton: Finalist - Annual Life Science Award 2017

13/01/2017

ReproCELL Europe Ltd's CEO, Dr David Bunton, is one of the finalists nominated for the Life Science Business Leadership Award, part of Scotland's Annual Life Science Awards and Dinner, 2017.

The award ceremony will take place on 2nd February 2017.

Venue: National Museum of Scotland (Edinburgh, UK).

Live chat by BoldChat